乙型肝炎病毒(HBV)DNA免疫的初步研究

用聚合酶链反应（ＰＣＲ）扩增了编码ＨＢＶｓＡｇ的基因序列,将其插入到ｐｃＤＮＡ３载体中,位于人巨细胞病毒（ＣＭＶ）早期启动子下游．重组质粒ｐｃＤＮＡ３－ｓＡｇ转染细胞后检测到ＨＢｓＡｇ表达．用纯化后的重组质粒直接注射到ＢＡＬＢ／Ｃ小鼠骨骼肌内,诱发实验小鼠产生了抗ＨＢｓＡｇ特异性抗体．ＰＣＲ扩增未检测到注射部位及肝脏细胞染色体中有外源ＨＢＶＤＮＡ整合     

乙型肝炎表面抗原基因DNA介导的体液免疫初步研究

用ＣＰＲ技术从纯化的乙型肝炎病毒核酸中扩增出ｐｅｒＳ２－Ｓ基因,并将其定向克隆于真核表达质粒ｐｃＤＮＡ３．１（＋）中,构建成带有完整的乙肝表面前Ｓ２抗原基因和Ｓ基因的重组质粒。重组质粒经酶切及部分序列分析鉴定后,瞬时转梁小鼠Ｌ细胞,ＥＬＩＳＡ法检测到培养上清液有ＨＢｓＡｇ表达。用纯化的重组质粒静脉、肌肉和皮下注射免疫ＢＡＬＢ／ｃ小鼠,首次接种质粒ＤＮＡ３周后,血清抗体开始出现,再次加强２周后,阳性     

乙型肝为病毒（HBV）DNA免疫的初步研究

用聚合酶链反应（ＰＣＲ）扩增了编码ＨＢＶｓＡｇ的基因序列,将其插入到ｐｃＤＮＡ３载体中,位于人巨细胞病毒（ＣＭＶ）早期启动子下游,重组质粒ｐｃＤＮＡ３－ｓＡｇ转染细胞后检测到ＨＢｓＡｇ表达,用纯化后的重组质粒直接注射用ＢＡＬＢ／Ｃ小鼠骨骼细内,诱发实验小鼠产生了抗ＨＢｓＡｇ特异性抗体,ＰＣＲ扩增未检测到注射部位及肝脏细胞染色体中有外源ＨＢＶＤＮＡ整合。     

AcNPV增强子hr5增强HBsAg基因表达的研究

用形成包涵体（ＯＯＣ＋）并能利用人工合成启动序列和多角体ＸＩＶ启动子表达外源基因的转移载体质粒ｐＳＸＩＶＶＩ＋Ｘ３将多角体基因、乙型肝炎病毒表面抗原（ＨＢＳＡｇ）基因和苜蓿丫纹夜蛾核型多角体病毒（ＡｃＮＰＶ）的增强子ｈｒ５部分序列同时插入无包涵体的粉纹夜蛾核型多角体病毒ＴｎＮＰＶ－ＳＶＩ－Ｇ基因组中，得到两株高效表达ＨＢｓＡｇ基因又形成包涵体的重组病毒ＴｎＮＰＶ－ｓｈｒ３５－ＯＣＣ＋和ＴｎＮＰＶ－ｓｈｒ２６－ＯＣＣ＋．对重组病毒的酶切鉴定、ＤＮＡ斑点杂交和Ｓｏｕｔｈｅｒｎｂｌｏｔ分析证实，外源基因及其相应的启动子和增强子序列已正确插入病毒基因组中．插入顺序中，ｈｒ５增强子是插入ＨＢｓＡｇ基因下游，多角体基因与ＨＢｓＡｇ基因方向相反．１２５Ⅰ－固相放射免疫检测和Ｗｅｓｔｅｒｎｂｌｏｔ结果表明，ＨＢｓＡｇ基因在昆虫离体细胞中得到高效表达并保留了抗原活性．ＴｎＮＰＶ－ｓｈｒ２６－ＯＣＣ＋和ＴｎＮＰＶ－ｓｈｒ３５－ＯＣＣ＋表达的ＨＢｓＡ吕蛋白与没有插入增强子序列的重组病毒ＴｎＮＰＶ—ＨＢｓ８５－ＯＣＣ＋的比较，分别提高了４０％和４６％．     

鸭乙肝病毒表面抗原特异性单抗的研制及应用

以纯化的鸭乙型肝炎病毒表面抗原（ＤＨＢｓＡｇ）免疫ＢＡＬＢ／ｃ小鼠,取免疫鼠脾细胞与小鼠骨髓瘤ＳＰ２／Ｏ－Ａｇ１４融合,应用ＥＬＩＳＡ筛选出５Ｂ８和８Ｇ１１ ２株抗体分泌滴度较高的杂交瘤细胞,二者所分泌的单抗仅与ＤＨＢｓＡｇ发生反应,而与其它９种禽类常见的病毒均不发生反应,其亚类鉴定分别属于ＩｇＭ和ＩｇＧ２ａ。用鸭乙型肝炎病毒（ＤＨＢＶ）阳性鸭血清中粗提的病毒悬液进行５Ｂ８株单抗介导的ＳＰＡ胶体金     

丙型肝炎病毒核酸疫苗的研究

从丙型肝炎病人的阳性血清中提取出丙型肝炎病毒ＲＮＡ，通过ＲＴ－ＰＣＲ的方法获得丙型肝炎病毒Ｃ区基因片段。并将此片段克隆到真核细胞表达载体ｐｃＤＮＡ３．１（＋），得到重组质粒ｐｃＤＮＡ－ＨＣＶ／Ｃ，再将其通过肌肉注射免疫ＢＡＬＢ／小鼠后，小鼠产生了抗ＨＣＶ／Ｃ区抗体。     

具全期启动子盒的杆状病毒高效表达载体的组建与应用

通过ＰＣＲ扩增，得到苜蓿丫纹夜蛾核型多角体病毒（ＡｕｔｏｇｒａｐｈａｃａｌｉｆｏｒｎｉｃａＮｕｃｌｅａｒＰｏｌｙｈｅｄｒｏｓｉｓＶｉｒｕｓ，ＡｃＮＰＶ）具早晚期启动子元件的ｐ３５基因启动子，将其插入到杆状病毒转移载体质粒ｐＳＸＩＶＶＩ＋Ｘ３多克隆位点上游，使之与ｐＳＸＩＶＶＩ＋Ｘ３质粒中的人工合成后期启动子（ＰＳｙｎ）、多角体ＸＩＶ启动子（ＰＸＩＶ）串联构成早期、晚期、极晚期能持续启动外源基因表达的转移载体质粒ｐＳＸ３５．将ｐＳＸ３５用于组建含ＨＢｓＡｇ基因并形成多角体的重组ＴｎＮＰＶ，ＨＢ－ｓＡｇ基因的表达量显著提高，表达时间亦明显提前，从而实现了外源基因在杆状病毒表达系统的全期、高效表达．ｍＲＮＡ引物延伸试验结果显示，Ｐｐ３５在重组病毒中可产生２套转录本，分别于病毒感染的早期和晚期起始ＨＢｓＡｇ基因的表达．     

斜纹夜蛾NPV多角体基因的克隆和部分测序

本文对ＳＩＮＰＶ基因组作了酶解分析，测得其基因组大小为１４５ｋｂ，并用双酶法确定了ＳＩＮＰＶ基因组的ＨｉｎｄⅢ和ＰｓｔⅠ物理图谱。以含ＡｃＮＰＶ多角体基因的质粒ｐＡＣ－Ⅰ的ＳａｌＩ－Ｃ片段为探针，对ＳＩＮＰＶＤＮＡ酶切片段ｓｏｕｔｈｅｒｎ转印杂交结果，初步判断多角体基因定位于ＰｓｔＩ－Ｂ／Ｃ／Ｄ片段、ＢｇｌⅡ－Ｃ／Ｄ片段、ＢａｍＨＩ－Ｂ／Ｃ片段和ＥｃｏＲＩ－Ａ／Ｂ片段上，且ＳＩＮＰＶ与ＡｃＮＰＶ多角体蛋白基因有６４％的同源性，而以大肠仟菌质粒ｐＵＣ１９为载体对ＳＩＮＰＶ的多角体基因试克隆，得到带有ＢｇｌⅡ－ＰｓｔⅠ双酶切片段的２个克隆子。对这两个杂交阳性克隆子之一的核苷酸序列测定，表明插入片段与ＢｍＮＰＶ多角体基因上游序列亦有一定同源性。     

可溶性白细胞介素6受体β亚基在重组痘苗病毒中的表达及其对动物的免疫效果

目的：构建可溶性白细胞介素６受体（ＩＬ－６Ｒ）β亚基（ｓｇｐ１３０）重组痘苗病毒，感染动物细胞使其表达ｓｇｐ１３０，用重组病毒免疫动物产生特异性抗ｓｇｐ１３０抗体。方法：将ｓｇｐ１３０基因导入痘苗病毒载体ｐＪＳＡ１１７５，用脂质体转染法将重组载体与野生型痘苗病毒在ＴＫ－１４３细胞中发生同源重组，用ＢｕｄＲ和Ｘ－ｇａｌ双重选择，得到带有人ｓｇｐ１３０的重组病毒（Ｖｓｇｐ１３０）。结果：采用ＩＤＡ和ＷｅｓｔｅｒｎＢｌｏｔｉｎｇ法证实，感染Ｖｓｇｐ１３０的ＴＫ－１４３细胞上清中有较强的ｓｇｐ１３０表达，表达产物分子量为１０００００左右。用重组病毒免疫家兔和Ｂａｌｂ／ｃ小鼠，可刺激抗体产生。结论：ｓｇｐ１３０在痘苗病毒载体系统中的表达成功及抗ｓｇｐ１３０多克隆抗体的产生为进一步研究ＩＬ－６等细胞因子信号传导机理及研制抗ｓｇｐ１３０单克隆抗体奠定了基础。     

Bc1-2 基因加强表达对 OA 诱发的细胞编程死亡的效应

ＯＡ能诱发人神经母细胞瘤ＳＫ细胞进行编程死亡．死亡细胞缩小变圆，细胞质凝聚，ＤＮＡ有控降解成约２００ｂｐ左右的片段，且这一过程可由蛋白质合成抑制剂亚胺环己酮（ＣＨＸ）抑制．将编码Ｂｃ１－２全长蛋白质的ｃＤＮＡ植入ｐＸＪ４１ｎｅｏ载体中，使其表达由ＨＣＭＶ病毒启动子控制．形成的顺义（ｐＢｃｌ－２－Ｓ）及反义（ｐＢｃｌ－２－ＡＳ）表达质粒经转染导入ＳＫ细胞中获得稳定转染子，Ｗｅｓｔ－ｅｒｎ印迹表明顺义转染子表达较大量的２６ｋｄＢｃ１－２蛋白，而反义转染子则不表达．增强表达的Ｂｃ１－２基因产物对ＯＡ引ＳＫ细胞编程死亡无抑制效应．     

Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

The acquired immunodeficiency syndrome (AIDS) is the late-stage clinical manifestation of long-term persistent infection with the human immunodeficiency virus type 1 (HIV-1). Immune responses directed against the virus and against virus-infected cells during the persistent infection fail to mediate resolution of the infection. As a result, a successful AIDS vaccine must elicit an immune state that will prevent the establishment of the persistent infection following introduction of the virus into the host. The third hypervariable (V3) domain of the HIV-1 gp120 envelope glycoprotein is a disulphide-linked closed loop of about 30 amino acids which binds and elicits anti-HIV-1 type-specific virus-neutralizing antibodies. The in vitro characteristics of anti-V3 domain antibody suggest that this antibody could by itself prevent HIV-1 infection in vivo, an idea supported by chimpanzee challenge studies in which protection against the HIV-1 persistent infection seemed to correlate with the presence of anti-V3 domain antibody. Here we directly demonstrate the protective efficacy of anti-V3 domain antibody in vivo and propose that this antibody is potentially useful as both a pre- and post-exposure prophylactic agent.     

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

The development of a vaccine to provide protective immunity to human immunodeficiency virus type 1 (HIV-1), the virus causing AIDS, would be the most practical method to control its spread. Subunit vaccines consisting of virus envelope glycoproteins, produced by recombinant DNA technology, are effective in preventing viral infections. We have now used this approach in the development of a candidate AIDS vaccine. Chimpanzees were immunized with recombinant forms of the HIV-1 glycoproteins gp120 and gp160 produced in Chinese hamster ovary cells, and then challenged with HIV-1. The control and the two animals immunized with the gp160 variant became infected within 7 weeks of challenge. The two animals immunized with the gp120 variant have shown no signs of infection after more than 6 months. These studies demonstrate that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1.     

Predefined GPGRAFY-Epitope-Specific Monoclonal Antibodies with Different Activities for Recognizing Native HIV-1 gp120

A seven-amino acid epitope GPGRAFY at the tip of the V3 loop in HIV-1 gp120 is the principal neutralizing epitope, and a subset of anti-V3 antibodies specific for this epitope shows a broad range of neutralizing activity. GPGRAFY-epitope-specific neutralizing antibodies were produced using predefined GPGRAFY-epitope-specific peptides instead of a natural or recombinant gp120 bearing this epitope. All six monoclonal antibodies (mAbs) could recognize the GPGRAFY-epitope on peptides and two of the antibodies, 9D8 and 2D7, could recognize recombinant gp120 in enzymelinked immunosorkentassy (ELISA) assays. In the flow cytometry analysis, the mAbs 9D8 and 2D7 could bind to HIV-Env CHO-WT cells and the specific bindings could be inhibited by the GPGRAFY-epitope peptide, which suggests that these two mAbs could recognize the native envelope protein gp120 expressed on the cell membrane. However, in syncytium assays, none of the mAbs was capable of inhibiting HIV-Env-mediated cell membrane fusion. The different activities for recognizing native HIV-1 gp120 might be associated with different antibody affinities against the epitopes. The development of conformational mimics of the neutralization epitope in the gp120 V3 loop could elicit neutralizing mAbs with high affinity.     

Monoclonal Antibodies Recognizing HIV-1 gp41 Could Inhibit Env-Mediated Syncytium Formation

Some monoclonal antibodies （mAbs） could inhibit infection by HIV-1. In this study, four mAbs against HIV-1 gp41 were prepared in mice. All four mAbs could bind to the recombinant soluble gp41 and recognize the native envelope glycoprotein gp160 expressed on the HIV-Env^＋ CHO-WT cell in flow cytometry analysis. Interestingly, the results show that all four mAbs purified by affinity chromatography could inhibit HIV-1 Env-mediated membrane fusion （syncytium formation） by 40%-60% at 10 μg/mL, which implies potential inhibitory activities against HIV-1.     

含CpG motifs的乙肝表面抗原载体的构建及表达

构建了编码乙肝表面抗原中蛋白的卡那霉素抗性真核表达质粒pVAX-CpGS2S，其中通过PCR克隆了若干CpG motifs到质粒载体中。经酶切鉴定和测序正确后将重组质粒体外转染COS7细胞，ELISA法检测上清液中的HBsAg呈阳性，说明重组质粒pVAX-CpGS2S在体外能够有效表达HBsAg，为探讨CpG motifs克隆入DNA疫苗载体后对体内免疫反应的影响打下基础。     

Biosynthesis of hepatitis B virus surface antigen in Escherichia coli

Hepatitis B is a widespread viral disease. In the absence of cell cultures capable of propagating the virus (HBV) an efficient vaccine has been prepared from viral envelopes isolated from the plasma of chronic carriers. The major polypeptide of the envelope is one of molecular weight 25,000 which carries the surface antigen (HBsAg). Therefore, the biosynthesis of this polypeptide in Escherichia coli may offer an alternative procedure to produce HbsAg free from human proteins. Recently, the HBV genome has been cloned in E.coli. Determination of its primary structure allowed the localization of the gene (called gene S) coding for HBsAg and the synthesis of the core antigen in E.coli has been reported. We have constructed a derivative of bacteriophage lambda carrying a fusion between the beta-galactosidase gene (lacZ) and the HBsAg coding sequence (lambdalacHBs-1). Infection of E.coli with lambdalacHBs-1 leads to the biosynthesis of a polypeptide of molecular weitht 138,000 carrying antigenic determinants of HBV surface antigen.     

表达HIV-1复合多表位基因的p815细胞稳定株的建立和评价

建立稳定表达HIV-1p24MEG复合多表位基因的p815细胞克隆.设计引物,以HIV-1标准株全长cDNA序列为模板,PCR扩增获得p24基因片段;合成改造后的多个表位基因MEG并且与p24片段相连接,克隆入pcDNA3.1(+).在阳离子聚合物作用下重组真核质粒转染的p815(H-2d)细胞, 以G418压力筛选,RT-PCR检测mRNA表达,间接免疫荧光检测蛋白表达.通过PCR获得了HIV-1 p24片段,获得了与多表位基因连接后的p24MEG融合基因,成功构建了p24MEG基因的重组真核表达载体pcDNA3.1(+)/p24MEG.转染p815细胞后, RT-PCR检测到融合蛋白mRNA表达,间接免疫荧光显示 p815细胞内有融合蛋白的表达.结论:建立了稳定表达HIV-1p24MEG融合蛋白的p815细胞克隆,为评价多表位抗原p24MEG在BALB/c小鼠体内诱导的细胞免疫应答奠定基础.     

Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant

OBJECTIVE: To investigate the effect of interleukin-18 (IL-18) on immune response induced by plasmid encoding hepatitis B virus middle protein antigen and to explore new strategies for prophylactic and therapeutic HBV DNA vaccines. METHODS: BALB/c mice were immunized with pCMV-M alone or co-immunized with pcDNA3-18 and pCMV-M and then their sera were collected for analysing anti-HBsAg antibody by ELISA; splenocytes were isolated for detecting specific CTL response and cytokine assay in vitro. RESULTS: The anti-HBs antibody level of mice co-immunized with pcDNA3-18 and pCMV-M was slightly higher than that of mice immunized with pCMV-M alone, but there was not significantly different (P>0.05). Compared with mice injected with pCMV-M, the specific CTL cytotoxity activity of mice immunized with pcDNA3-18 and pCMV-M was significantly enhanced (P<0.05) and the level of IFN-Gamma in supernatant of splenocytes cul-tured with HBsAg in vitro was significantly elevated (P<0.05) while the level of IL-4 had no significant difference (P>0.05). CONCLUSION: The plasmid encoding IL-18 together with HBV M gene DNA vaccines may enhance specific TH1 cells and CTL cellular immune response induced in mice, so that IL-18 is a promising immune adjuvant.     

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

The nucleocapsid (HBcAg) of the hepatitis B virus (HBV) can induce antibody responses via both a T-cell dependent and a T-cell independent pathway and is highly immunogenic during infection. We have examined the T-cell determinants of the antigen and find that HBcAg-specific helper T cells (TH) can help B cells produce antibody against envelope (HBsAg) antigens as well as HBcAg, even though these antigens are found on separate molecules. We have also been able to prime helper T cells with synthetic T-cell epitopes of HBcAg; helper cells primed with a single synthetic epitope can induce B cells to produce antibody that reacts with multiple HBsAg epitopes. One problem with the development of an HBV vaccine is that some vaccinees and patients do not respond to HBsAg directly; our results indicate that this problem can be circumvented using the response to HBcAg.